G90.B
LMNB1-related autosomal dominant leukodystrophy
Clinical Classification Guidelines
Medical Intelligence & Overview
LMNB1-related autosomal dominant leukodystrophy is a rare genetic disorder that affects the brain's white matter, leading to progressive neurological symptoms. Characterized by abnormalities in the gene that produces lamin B1, this condition results in the degeneration of the protective covering of nerve fibers, which impairs nerve signaling. Symptoms often develop in adulthood and can significantly impact motor functions, cognition, and daily living activities. Due to its genetic nature, it is inherited in an autosomal dominant pattern, meaning only one copy of the altered gene is sufficient to cause the disorder.
Causes & Symptoms
Clinical Causes: Mutations or duplications in the LMNB1 gene on chromosome 5q23.2 Inheritance of the mutant gene from an affected parent (autosomal dominant transmission) No known environmental factors directly cause the condition Genetic variations that lead to abnormal lamin B1 protein production, causing white matter degeneration
Key Symptoms: Progressive difficulties with balance and coordination Muscle weakness and stiffness Problems with speech and swallowing Cognitive decline, including memory and concentration issues Behavioral changes, including mood swings or psychiatric symptoms Gait abnormalities leading to instability when walking Possible bladder or bowel control issues in later stages Sensory disturbances such as numbness or tingling in limbs
Diagnostic & Treatment
Diagnosis Path: The diagnosis of LMNB1-related leukodystrophy involves a combination of clinical assessment, neuroimaging, and genetic testing. Magnetic resonance imaging (MRI) typically reveals characteristic white matter abnormalities, such as widespread demyelination and changes in brain structure. Confirmatory diagnosis is made through genetic testing, which identifies duplications or mutations in the LMNB1 gene. Family history may also guide physicians in suspecting inherited cases. Additional testing might include neuropsychological evaluation to assess cognitive functions and rule out other neurological conditions.
Treatment Protocols: Currently, there is no cure for LMNB1-related leukodystrophy. Management focuses on addressing symptoms and improving quality of life. This can involve physical therapy to maintain mobility, speech therapy for communication difficulties, and occupational therapy to assist with daily activities. Medications may be prescribed for specific symptoms such as spasticity, seizures, or behavioral issues. Regular monitoring by a multidisciplinary team is recommended to adapt care plans as the disease progresses. Supportive measures, including counseling and support groups, can provide emotional assistance for patients and their families.
Clinical Advice & FAQs
Billing Guidance
Is G90.B a billable ICD-10 code?
Yes, G90.B is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G90.B?
Clinical documentation must specify the nature of LMNB1-related autosomal dominant leukodystrophy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference